118. From molecular signatures to predictive biomarkers: Modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol 2014, 2:37
Heinzel A, Perco P, Mayer G, Oberbauer R, Lukas A, Mayer B
// Publications
117. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials 2014, 15:107-115. (IF 2)
Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA
116. A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND. PLOS ONE 2014; 9(9): e106631. (IF 2.9)
Shiffman D, Paré G, Oberbauer R, Louie JZ, Rowland CM, Devlin JJ, Mann JF, McQueen MJ.
115. Molecular pathogeneses of post-transplant Acute Kidney Injury: assessment of whole-genome mRNA and miRNA profiles. PLOS ONE 2014; 9(8): e104164. (IF 2.9)
Wilflingseder J, Sunzenauer J, Toronyi E, Heinzel A, Kainz A, Mayer B, Perco P, Telkes G, Langer RM, Oberbauer R.